Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRAX Praxis Precision Medicines, Inc.

交易中 04-07 12:39:45 EDT

303.00

-7.11

-2.29%

最高310.00	最低301.25	成交量10.23万
今开309.41	昨收310.11	日振幅2.82%
总市值84.39亿	流通市值78.11亿	总股本2,785万
成交额3,115万	换手率0.40%	流通股本2,578万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":303,"timestamp":1775579984018,"preClose":310.11,"halted":0,"volume":102338,"delay":0,"changeRate":-0.022927348360259305,"floatShares":25778700,"shares":27850833,"eps":-13.475777,"marketStatus":"交易中","change":-7.11,"latestTime":"04-07 12:39:45 EDT","open":309.41,"high":310,"low":301.25,"amount":31149824.6484,"amplitude":0.028216,"askPrice":304.95,"askSize":9,"bidPrice":303.06,"bidSize":216,"shortable":3,"etf":0,"ttmEps":-13.475777,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775592000000},"marketStatusCode":2,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":310.11,"preHourTrading":{"tag":"盘前","latestPrice":310.04,"preClose":310.11,"latestTime":"09:26 EDT","volume":5,"amount":1543.3899999999999,"timestamp":1775568384416,"change":-0.07,"changeRate":-0.000226,"amplitude":0.02196},"postHourTrading":{"tag":"盘后","latestPrice":310.11,"preClose":310.11,"latestTime":"18:30 EDT","volume":26431,"amount":8196545.76,"timestamp":1775514601171,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.473531,"impliedVol":0.8318,"impliedVolPercentile":0.408},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"1158299786","title":"Praxis Precision Medicines公司：Elsunersen在最高8毫克剂量下耐受性良好，未出现药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1158299786","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158299786?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:03","pubTimestamp":1775477038,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，其研究药物Elsunersen在临床试验中表现出良好的耐受性。数据显示，在剂量递增至8毫克的范围内，未观察到任何与药物相关的严重不良事件。这一结果进一步支持了该候选药物的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0009355771.USD","LU0889565916.HKD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4139","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PRAX","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112964089","title":"Praxis精准医疗公布Elsunersen治疗SCN2A早发性发育性癫痫性脑病的Embrave试验A部分积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112964089","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112964089?lang=zh_cn&edition=full","pubTime":"2026-04-06 20:01","pubTimestamp":1775476874,"startTime":"0","endTime":"0","summary":"Praxis精准医疗公司近日宣布，其针对SCN2A早发性发育性癫痫性脑病研发的药物Elsunersen，在Embrave临床试验的A阶段取得了积极的研究成果。该试验数据表明，Elsunersen在目标患者群体中展现出良好的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","PRAX","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191234265","title":"Praxis Precision Medicines公司宣布：FDA为Relutrigine设定PDUFA目标行动日期为2026年9月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1191234265","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191234265?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:02","pubTimestamp":1774900932,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司披露，美国食品药品监督管理局（FDA）已为其在研药物Relutrigine设定了处方药使用者费法案（PDUFA）的目标行动日期，定于2026年9月27日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","PRAX","LU0320765992.SGD","LU0109394709.USD","IE0009355771.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154860007","title":"Praxis Precision Medicines公司Relutrigine治疗广泛性癫痫的Emerald试验预计2026年底完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1154860007","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154860007?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:02","pubTimestamp":1774900930,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司近日公布，其研发的Relutrigine针对广泛性癫痫适应症的Emerald临床试验，预计将于2026年底前完成。该试验的进展备受市场关注，其结果将对公司未来发展产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180757495","title":"Praxis Precision Medicines公布公司最新动态及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1180757495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180757495?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:31","pubTimestamp":1771504278,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.（简称Praxis）近日披露了公司运营进展及2025年第四季度与全年财务报告。此次公告涵盖关键业务里程碑与财务数据，为投资者提供全面战略视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","PRAX","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105033186","title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","url":"https://stock-news.laohu8.com/highlight/detail?id=1105033186","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105033186?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:44","pubTimestamp":1770864278,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.将于2026年02月19日发布最新财报，市场关注其本季度营收与利润拐点的可见性以及研发推进节奏对亏损收窄的影响。由于当前缺乏披露毛利率与净利率的预测口径，相关指标暂无一致预估。上一财季管理层未提供可量化的本季度营收、毛利率、净利润或净利率、调整后每股收益等预测口径。基于公开渠道收集的区间内观点，机构对Praxis Precision Medicines, Inc.的态度以审慎偏中性为主，尚未形成明确的一边倒看多或看空共识。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157558681","title":"富国银行首次覆盖Praxis Precision Medicines 给予持股观望评级 目标价282美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157558681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157558681?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:36","pubTimestamp":1770035783,"startTime":"0","endTime":"0","summary":"富国银行发布最新研报，宣布对精准医疗公司Praxis Precision Medicines, Inc. (PRAX) 启动覆盖研究。该机构给予该公司\"持股观望\"评级，同时设定目标股价为每股282美元。\n此次覆盖标志着华尔街对这家生物技术企业的关注度提升。分析师在报告中指出，虽然公司在新药研发领域展现潜力，但当前估值已基本反映其成长前景，因此建议投资者保持谨慎乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","PRAX","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","BK4139","LU0109394709.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128938615","title":"Praxis Precision Medicines任命全球癫痫领域权威Orrin Devinsky博士担任临床战略负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=1128938615","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128938615?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:31","pubTimestamp":1768339876,"startTime":"0","endTime":"0","summary":"精准医疗公司Praxis Precision Medicines, Inc.宣布一项重要人事任命：全球癫痫治疗领域的顶尖专家Orrin Devinsky博士正式加入公司，出任临床战略负责人。这一战略布局彰显了Praxis深耕神经系统疾病治疗领域的决心。此次任命被视为Praxis加速推进其神经科学管线的重要里程碑。公司表示，Devinsky博士的专业洞察将直接应用于核心项目的临床开发路径优化，助力提升临床试验效率与成功率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","PRAX","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B2B36J28.USD","BK4139","LU0320765992.SGD","LU0109394709.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178329341","title":"Praxis Precision Medicines公司预计2026年2月中旬前提交两款新药申请：Ulixacaltamide用于特发性震颤及Relutrigine用于SCN2A/8A相关疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1178329341","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178329341?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:08","pubTimestamp":1768223296,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，针对其在研药物Ulixacaltamide与Relutrigine的两项新药申请（NDA），预计将于2026年2月中旬前提交。其中，Ulixacaltamide的适应症为特发性震颤，而Relutrigine则旨在治疗与SCN2A及SCN8A基因相关的疾病。这一进展标志着公司在推进其精准医疗管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","PRAX","IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105658123","title":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1105658123","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105658123?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:01","pubTimestamp":1765458098,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108126706","title":"Praxis Precision Medicines, Inc.：Embrave研究（A部分，N=9）的主要结果预计将在2026年上半年发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1108126706","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108126706?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:03","pubTimestamp":1765314199,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：Embrave研究（A部分，N=9）的主要结果预计将在2026年上半年发布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156451905","title":"Praxis Precision Medicines宣布与FDA达成一致，对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1156451905","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156451905?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:02","pubTimestamp":1765314150,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines宣布与FDA达成一致，对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","PRAX","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196344993","title":"Praxis Precision Medicines, Inc.：FDA 同意对 Embrave3 试验设计进行拟议更改，成为单臂基线对照研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1196344993","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196344993?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:02","pubTimestamp":1765314132,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：FDA 同意对 Embrave3 试验设计进行拟议更改，成为单臂基线对照研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","PRAX","BK4139","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180993297","title":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1180993297","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180993297?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:47","pubTimestamp":1765230438,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4139","PRAX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130139994","title":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1130139994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130139994?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:12","pubTimestamp":1764882729,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","PRAX","LU0320765992.SGD","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199927050","title":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1199927050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199927050?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:02","pubTimestamp":1764882151,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166387197","title":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1166387197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166387197?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347693,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116109522","title":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1116109522","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116109522?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347691,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158510697","title":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1158510697","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158510697?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:01","pubTimestamp":1762261279,"startTime":"0","endTime":"0","summary":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106249696","title":"异动解读 | Praxis Precision Medicines股价盘中大涨9.97%，新药临床试验成功推动股价持续攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1106249696","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106249696?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:32","pubTimestamp":1760707948,"startTime":"0","endTime":"0","summary":"生物制药公司Praxis Precision Medicines周五盘中大涨9.97%，延续了前一交易日的强劲涨势。这一显著涨幅主要源于该公司实验性药物在临床试验中取得突破性进展，以及随后宣布的大规模融资计划。Praxis Precision Medicines本周早些时候宣布，其用于治疗本质性震颤的实验性药物ulixacaltamide在两项关键性三期临床试验中均达到了预定的主要终点。紧随临床试验成功之后，Praxis宣布了一项5.25亿美元的公开募股计划。Praxis Precision Medicines股价的持续上涨反映了投资者对公司未来发展前景的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7fa23516ca85b1156f2152e8f7e5531d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.1218},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.1364},{"period":"6month","weight":4.7121},{"period":"1year","weight":8.498},{"period":"ytd","weight":0.0521}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Praxis Precision Medicines, Inc.于2015年9月22日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，将遗传见解转化为中枢神经系统（CNS）治疗方法的发展，CNS是以神经元失衡为特征的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.021596},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}